Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma.
Gupta S, Albertson DJ, Parnell TJ, Butterfield A, Weston A, Pappas LM, Dalley B, O'Shea JM, Lowrance WT, Cairns BR, Schiffman JD, Sharma S.
Gupta S, et al. Among authors: parnell tj.
Mol Cancer Ther. 2019 Jan;18(1):185-195. doi: 10.1158/1535-7163.MCT-17-0957. Epub 2018 Oct 9.
Mol Cancer Ther. 2019.
PMID: 30301863
Free PMC article.